Download PDF
Semin intervent Radiol 2014; 31(01): 086-090
DOI: 10.1055/s-0033-1363847
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Role of Radiation Therapy for Renal Tumors

Bhupesh Parashar
1   Stich Radiation Center, Weill Cornell Medical Center, New York, New York
,
Kanhu Charan Patro
2   Mahatma Gandhi Cancer Hospital, Visakhapatnam, Andhra Pradesh, India
,
Michael Smith
1   Stich Radiation Center, Weill Cornell Medical Center, New York, New York
,
Shruthi Arora
1   Stich Radiation Center, Weill Cornell Medical Center, New York, New York
,
Dattatreyudu Nori
1   Stich Radiation Center, Weill Cornell Medical Center, New York, New York
,
A. Gabriella Wernicke
1   Stich Radiation Center, Weill Cornell Medical Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
20 February 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Renal cell carcinoma (RCC) is an aggressive malignancy that carries a poor prognosis, especially in patients presenting with advanced stage. Primary treatment for localized RCC is surgical resection however, a significant number of patients still develop locoregional and distant metastasis after curative resection. In metastatic disease, radiation therapy (RT) has been used for palliation routinely for brain and other extracranial lesions with respectable response rates. However, RT for primary RCC has questionable benefit. In this article, the authors discuss the evidence with regards to the role of RT in primary RCC either as a primary treatment, adjuvant treatment, or preoperatively to improve resection outcomes. In addition, novel RT techniques such as stereotactic body radiation therapy and its use in RCC management are also addressed. Finally, the authors discuss the techniques and doses of RT for primary RCC.

Keywords

renal - radiation - stereotactic - intensity-modulated radiation therapy - role
 

  • References

  • 1 Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 2013; 7: 139-148
    PubMedGoogle Scholar
  • 2 Sun M, Thuret R, Abdollah F , et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011; 59 (1) 135-141
    CrossrefPubMedGoogle Scholar
  • 3 Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113 (1) 78-83
    CrossrefPubMedGoogle Scholar
  • 4 Cindolo L, Chiodini P, Gallo C , et al. Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2008; 113 (1) 65-71
    CrossrefPubMedGoogle Scholar
  • 5 Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001; 91 (2) 354-361
    CrossrefPubMedGoogle Scholar
  • 6 Zigeuner R, Hutterer G, Chromecki T , et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 2010; 57 (1) 102-109
    CrossrefPubMedGoogle Scholar
  • 7 Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 1997; 80 (12, Suppl): 2519-2528
    CrossrefPubMedGoogle Scholar
  • 8 Otto U, Huland H, Baisch H, Klöppel G. Transplantation of human renal cell carcinoma into NMRI nu/nu mice. III. Effect of irradiation on tumor acceptance and tumor growth. J Urol 1985; 134 (1) 170-174
    PubMedGoogle Scholar
  • 9 Kijima T, Koga F, Fujii Y, Yoshida S, Tatokoro M, Kihara K. Zoledronic acid sensitizes renal cell carcinoma cells to radiation by downregulating STAT1. PLoS ONE 2013; 8 (5) e64615
    CrossrefPubMedGoogle Scholar
  • 10 Frydenberg M, Gunderson L, Hahn G, Fieck J, Zincke H. Preoperative external beam radiotherapy followed by cytoreductive surgery and intraoperative radiotherapy for locally advanced primary or recurrent renal malignancies. J Urol 1994; 152 (1) 15-21
    PubMedGoogle Scholar
  • 11 Gay HA, Michalski JM. Cancer of the kidney, renal pelvis, and ureter. In: Halperin EC, Wazer DE, Perez CA, Brady LW, , eds. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia, PA: LWW; 2008: 1403-1404
    Google Scholar
  • 12 van der Werf-Messing B. Proceedings: Carcinoma of the kidney. Cancer 1973; 32 (5) 1056-1061
    CrossrefPubMedGoogle Scholar
  • 13 van der Werf-Messing B, van der Heul RO, Ledeboer RC. Renal adenocarcinoma; a prospective therapy study in Rotterdam [in Dutch]. Ned Tijdschr Geneeskd 1980; 124 (31) 1298-1303
    PubMedGoogle Scholar
  • 14 Juusela H, Malmio K, Alfthan O, Oravisto KJ. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 1977; 11 (3) 277-281
    CrossrefPubMedGoogle Scholar
  • 15 Stein M, Kuten A, Halpern J, Coachman NM, Cohen Y, Robinson E. The value of postoperative irradiation in renal cell cancer. Radiother Oncol 1992; 24 (1) 41-44
    CrossrefPubMedGoogle Scholar
  • 16 Kao GD, Malkowicz SB, Whittington R, D'Amico AV, Wein AJ. Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology 1994; 193 (3) 725-730
    PubMedGoogle Scholar
  • 17 Makarewicz R, Zarzycka M, Kulińska G, Windorbska W. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 1998; 45 (6) 380-383
    PubMedGoogle Scholar
  • 18 Kjaer M, Iversen P, Hvidt V , et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987; 21 (4) 285-289
    CrossrefPubMedGoogle Scholar
  • 19 Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13 (5) 665-672
    CrossrefPubMedGoogle Scholar
  • 20 Beitler JJ, Makara D, Silverman P, Lederman G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol 2004; 27 (6) 646-648
    CrossrefPubMedGoogle Scholar
  • 21 Wersäll PJ, Blomgren H, Lax I , et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 2005; 77 (1) 88-95
    CrossrefPubMedGoogle Scholar
  • 22 Svedman C, Sandström P, Pisa P , et al. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 2006; 45 (7) 870-875
    CrossrefPubMedGoogle Scholar
  • 23 Svedman C, Karlsson K, Rutkowska E , et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 2008; 47 (8) 1578-1583
    CrossrefPubMedGoogle Scholar
  • 24 Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int 2012; 110 (11 Pt B): E737-E743
    CrossrefPubMedGoogle Scholar
  • 25 Teh B, Bloch C, Galli-Guevara M , et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed Imaging Interv J 2007; 3 (1) e6
    PubMedGoogle Scholar